# US 2016/0355826 A1 · Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355826 A1
- Document ID: US20160355826A1
- Status: Published application
- Kind: A1
- Application number: 15/089,437
- Filed: 2016-04-01
- Published: 2016-12-08
- Earliest claimed: 2015-04-03
- Assignees: University of Massachusetts; Beth Israel Deaconess Medical Center, Inc.
- Applicants: University of Massachusetts; Beth Israel Deaconess Medical Center, Inc.
- Inventors: Anastasia Khvorova; Melissa Moore; Anton A. Turanov; Ananth Karumanchi
- Web page: https://patentgrep.com/patent/US20160355826A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12N 2310/50: Physical structure
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.

## Claims

### Claim 1

A compound that binds to an intronic region of an mRNA encoding an sFLT1 protein, wherein the compound selectively inhibits expression of the sFLT1 protein in a cell or organism.

### Claim 2 (depends on 1)

The compound of claim 1, comprising a single stranded (ss) RNA molecule or a double stranded (ds) RNA molecule that is between 15 and 35 bases in length, wherein the dsRNA molecule optionally mediates degradation of the mRNA.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The compound of claim 2, comprising a dsRNA having a sense strand and an antisense strand, wherein the antisense strand comprises a region of complementarity which is substantially complementary to
5′ CTCTCGGATCTCCAAATTTA 3′ (SEQ ID NO:1),
5′ CATCATAGCTACCATTTATT 3′ (SEQ ID NO:2),
5′ ATTGTACCACACAAAGTAAT 3′ (SEQ ID NO:3) or
5′ GAGCCAAGACAATCATAACA 3′ (SEQ ID NO:4), or
contains no more than 3 mismatches with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4,
wherein the dsRNA optionally:
mediates degradation of the mRNA;
is blunt-ended;
comprises naturally occurring nucleotides;
reduces expression of the sFLT1 protein in the cell or organism from about 30% to about 50%: or
reduces expression of the sFLT1 protein in the cell or organism from about 30% to about 40%.

### Claim 5 (depends on 4)

The dsRNA of claim 4, wherein said region of complementarity:
is complementary to at least 15, 16, 17 or 18 contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4;
contains no more than 3 mismatches with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4; or
is fully complementary to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 4)

The dsRNA of claim 4, wherein said dsRNA:
is blunt-ended and optionally;
comprises at least one single stranded nucleotide overhang;
comprises naturally occurring nucleotides; or
comprises at least one modified nucleotide.

### Claim at position 9

9-11. (canceled)

### Claim 12 (depends on 8)

The dsRNA of claim 8, wherein:
said modified nucleotide is chosen from the group consisting of a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative, a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide; or
said dsRNA comprises at least one 2′-O-methyl modified nucleotide, at least one 2′-fluoro modified nucleotide, at least one nucleotide comprising a 5′ phosphorothioate group and a terminal nucleotide linked to a cholesteryl derivative.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 2)

The dsRNA of claim 2, said dsRNA having a 5′ end, a 3′ end and complementarity to a target, and comprising a first oligonucleotide and a second oligonucleotide, wherein:
(1) the first oligonucleotide comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4;
(2) a portion of the first oligonucleotide is complementary to a portion of the second oligonucleotide;
(3) the second oligonucleotide comprises alternating 2′-methoxy-ribonucleotides and 2′-fluoro-ribonucleotides;
(4) the nucleotides at positions 2 and 14 from the 3′ end of the second oligonucleotide are 2′-methoxy-ribonucleotides; and
(5) the nucleotides of the second oligonucleotide are connected via phosphodiester or phosphorothioate linkages;
optionally wherein:
the second oligonucleotide is linked to a hydrophobic molecule at the 3′ end of the second oligonucleotide;
the linkage between the second oligonucleotide and the hydrophobic molecule comprises polyethylene glycol or triethylene glycol;
the nucleotides at positions 1 and 2 from the 3′ end of second oligonucleotide are connected to adjacent nucleotides via phosphorothioate linkages; or
the nucleotides at positions 1 and 2 from the 3′ end of second oligonucleotide, and the nucleotides at positions 1 and 2 from the 5′ end of second oligonucleotide, are connected to adjacent ribonucleotides via phosphorothioate linkages.

### Claim at position 14

16-21. (canceled)

### Claim 22

A therapeutic compound that binds to an intronic region of an mRNA encoding an sFLT1 protein, wherein the therapeutic compound selectively reduces expression of the sFLT1 protein, and wherein the therapeutic compound reduces one or more symptoms of preeclampsia (PE), postpartum PE, eclampsia or Hemolysis/Elevated Liver enzymes/Low Platelet count (HELLP) syndrome when administered to a subject in need thereof.

### Claim 23 (depends on 22)

The therapeutic compound of claim 22, wherein:
the sFLT1 protein is selected from the group consisting of one or any combination of sFLT1-i13 short, sFLT1-i13 long and sFlt1-i15a;
the therapeutic compound comprises a first oligonucleotide and a second oligonucleotide, wherein the first oligonucleotide binds an intronic region of one or both of sFLT1-i13 short and sFLT1-i13 long, and the second oligonucleotide binds an intronic region of sFlt1-i15a; or
the therapeutic compound comprises a first oligonucleotide and a second oligonucleotide, wherein the first oligonucleotide and the second oligonucleotide are single stranded RNA (ssRNA) or double stranded RNA (dsRNA).

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 22)

The therapeutic compound of claim 22, comprising a first dsRNA comprising a first sense strand and a first antisense strand and a second dsRNA comprising a second sense strand and a second antisense strand, wherein the first antisense strand comprises a first region of complementarity which is substantially complementary to SEQ ID NO:1 and the second antisense strand comprises a second region of complementarity which is substantially complementary to SEQ ID NO:2, optionally wherein:
each dsRNA is between 15 and 35 base pairs in length;
said first region of complementarity is complementary to at least 15, 16, 17 or 18 contiguous nucleotides of SEQ ID NO:1 and wherein said second region of complementarity is complementary to at least 15, 16, 17 or 18 contiguous nucleotides of SEQ ID NO:2;
said first region of complementarity contains no more than 3 mismatches with SEQ ID NO:1 and wherein said second region of complementarity contains no more than 3 mismatches with SEQ ID NO:2;
said first region of complementarity is fully complementary to SEQ ID NO:1 and wherein said second region of complementarity is fully complementary to SEQ ID NO:2; or
each dsRNA comprises at least one single stranded nucleotide overhang.

### Claim at position 20

27-31. (canceled)

### Claim 32 (depends on 26)

The first and second dsRNAs of claim 26, wherein each dsRNA comprises at least one modified nucleotide, optionally wherein:
said modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative;
said modified nucleotide is chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide;
each dsRNA comprises at least one 2′-O-methyl modified nucleotide, at least one 2′-fluoro modified nucleotide, at least one nucleotide comprising a 5′ phosphorothioate group and a terminal nucleotide linked to a cholesteryl derivative; or
each dsRNA comprises at least one 2′-O-methyl modified nucleotide, at least one 2′-fluoro modified nucleotide, at least one nucleotide comprising a 5′ phosphorothioate group and a terminal nucleotide linked to a cholesteryl derivative.

### Claim at position 22

33-35. (canceled)

### Claim 36 (depends on 26)

The first and second dsRNAs of claim 26, wherein each dsRNA comprises a 5′ end, a 3′ end and complementarity to a target, wherein:
(1) the oligonucleotide comprises alternating 2′-methoxy-ribonucleotides and 2′-fluoro-ribonucleotides;
(2) the nucleotides at positions 2 and 14 from the 5′ end are not 2′-methoxy-ribonucleotides;
(3) the nucleotides are connected via phosphodiester or phosphorothioate linkages; and
(4) the nucleotides at positions 1-6 from the 3′ end, or positions 1-7 from the 3′ end, are connected to adjacent nucleotides via phosphorothioate linkages.

### Claim 37

A pharmaceutical composition comprising:
a first dsRNA comprising a first sense strand and a first antisense strand, wherein the first antisense strand comprises a region of complementarity which is substantially complementary to SEQ ID NO:1, and wherein the first antisense strand selectively targets one or both of an intronic region of sFLT-i13 short and an intronic region of sFLT-i13 long;
a second dsRNA comprising a second sense strand and a second antisense strand, wherein the second antisense strand comprises a region of complementarity which is substantially complementary to SEQ ID NO:2, and wherein the second antisense strand selectively targets an intronic region of sFLT-i15a; and
a pharmaceutically acceptable carrier.

### Claim 38 (depends on 37)

A method of treating or managing PE, postpartum PE, eclampsia or HELLP syndrome comprising administering to a subject in need of such treatment or management a therapeutically effective amount of the pharmaceutical composition of claim 37.

### Claim 39 (depends on 38)

The method of claim 38, wherein the pharmaceutical composition is administered intravenously or subcutaneously, optionally wherein:
sFLT1 protein expression is reduced in the subject by about 30% to about 50%; or
sFLT1 protein expression is reduced in the subject by about 30% to about 40%.

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42 (depends on 26)

A method of treating one or more symptoms of PE, postpartum PE, eclampsia or HELLP syndrome in a subject in need thereof, comprising administering to the subject the therapeutic compound of claim 26.

### Claim 43 (depends on 4)

A method of treating one or more symptoms of an angiogenic disorder in a subject in need thereof, comprising administering to the subject the compound of claim 4.

### Claim 44 (depends on 43)

The method of claim 43, wherein the angiogenic disorder is selected from the group consisting of PE, postpartum PE, eclampsia and HELLP syndrome.

### Claim 45 (depends on 15)

The nucleic acid of claim 15, wherein:
the hydrophobic molecule comprises an omega-3 fatty acid; or
the hydrophobic molecule comprises a molecule selected from the group consisting of: docosanoic acid (DCA), docosahexaenoic acid (DHA), lysophosphatidylcholine esterified DHA (g2-DHA) and eicosapentaenoic acid (EPA).

### Claim 46

(canceled)

### Claim 47 (depends on 45)

The nucleic acid of claim 45, wherein the hydrophobic molecule is DHA or g2-DHA.
